Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next ...

The nuclear pore complex protein RANBP2 has emerged as a critical factor in the development and progression of various solid ...

Scientists have developed a powerful new method for selectively and reversibly breaking connections between brain cells—a ...

The nuclear pore complex protein RANBP2 has emerged as a critical factor in the development and progression of various solid malignancies.

Colorectal cancer (CRC) remains one of the most prevalent and deadly cancers worldwide, with rising incidence linked to ...

Shenzhen Zhongge Biotechnology Co. Ltd. has described proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding agent coupled to interleukin-1 receptor-associated ...

The nuclear pore complex protein RANBP2 has emerged as a critical factor in the development and progression of various solid malignancies. As a SUMO ...

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today ...

Researchers developed a biomimetic nanovesicle that crosses the blood-brain barrier, degrades DNA repair proteins, and ...